Fertility Benefit Services Revenue was Progyny’s largest product and service line in fiscal 2025, bringing in $830.93M of $1.29B (64%).
| Product and Service | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Fertility Benefit Services Revenue | $510.15M | $676.30M | $830.93M | ||||
| Pharmacy Benefit Services Revenue | $276.77M | $412.30M | $457.73M | ||||
| Total | $786.91M | $1.09B | $1.29B |
Progyny brought in $1.29B from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 18.4% from $1.09B in fiscal 2023, the previous year with figures. Fertility Benefit Services Revenue was the largest at $830.93M (64.5%), ahead of Pharmacy Benefit Services Revenue at $457.73M (35.5%).
Compared with fiscal 2023, the previous year with figures, Fertility Benefit Services Revenue grew 22.9% to $830.93M and Pharmacy Benefit Services Revenue grew 11.0% to $457.73M. From fiscal 2022 to 2025, combined revenue from these lines grew from $786.91M to $1.29B, a compound annual growth rate of 17.9%. Fertility Benefit Services Revenue's share held steady at about 64.5%.
Progyny (PGNY) reports its revenue by product and service. In fiscal 2025, Fertility Benefit Services Revenue was its largest product and service line, bringing in $830.93M (64.5% of the total), followed by Pharmacy Benefit Services Revenue at $457.73M (35.5%).
Fertility Benefit Services Revenue was Progyny's largest product and service line in fiscal 2025, bringing in $830.93M, or 64.5% of the $1.29B total across its two product and service lines.
Every figure comes from Progyny's annual financial filings, as reported. Each line keeps the name Progyny gives it, and years follow its fiscal calendar.
Progyny's revenue by product and service goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.